File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Pivotal roles of Interleukin-17 as the Epicenter of Bone Loss Diseases

TitlePivotal roles of Interleukin-17 as the Epicenter of Bone Loss Diseases
Authors
Liao, CZhang, CYang, Y
KeywordsBone loss
IL-17
IL-17 receptor
Osteoclastogensis
Osteoclasts
Issue Date2017
PublisherBentham Science Publishers Ltd. The Journal's web site is located at http://www.bentham.org/cpd/index.htm
Citation
Current Pharmaceutical Design, 2017, v. 23 n. 41, p. 6302-6309 How to Cite?
DOI: http://dx.doi.org/10.2174/1381612823666170519120040
AbstractBone remodelling is a strictly regulated dynamic process between bone resorption and bone formation. Many factors are involved in the process and affect the dynamic balance. Inflammation-mediated bone loss is a major feature of various bone diseases, including periodontitis, rheumatoid arthritis (RA) and spondyloarthritis (SpA). Interleukin-17 (IL-17) plays an important role in inflammatory bone disease and could be an attractive therapeutic target. This review focuses on the osteoclastic effects of IL-17 in different cell types and summarizes the current knowledge of IL-17 signalling pathways. Typical IL-17–mediated bone destruction disorders are examined. The review also provides an overview of possible strategies for therapeutic intervention for inflammatory. © 2017 Bentham Science Publishers.
Persistent Identifierhttp://hdl.handle.net/10722/244799
ISSN
1381-6128
2023 Impact Factor: 2.6
2023 SCImago Journal Rankings: 0.586
ISI Accession Number ID
WOS:000425351700010

 

DC FieldValueLanguage
dc.contributor.authorLiao, C-
dc.contributor.authorZhang, C-
dc.contributor.authorYang, Y-
dc.date.accessioned2017-09-18T01:59:16Z-
dc.date.available2017-09-18T01:59:16Z-
dc.date.issued2017-
dc.identifier.citationCurrent Pharmaceutical Design, 2017, v. 23 n. 41, p. 6302-6309-
dc.identifier.issn1381-6128-
dc.identifier.urihttp://hdl.handle.net/10722/244799-
dc.description.abstractBone remodelling is a strictly regulated dynamic process between bone resorption and bone formation. Many factors are involved in the process and affect the dynamic balance. Inflammation-mediated bone loss is a major feature of various bone diseases, including periodontitis, rheumatoid arthritis (RA) and spondyloarthritis (SpA). Interleukin-17 (IL-17) plays an important role in inflammatory bone disease and could be an attractive therapeutic target. This review focuses on the osteoclastic effects of IL-17 in different cell types and summarizes the current knowledge of IL-17 signalling pathways. Typical IL-17–mediated bone destruction disorders are examined. The review also provides an overview of possible strategies for therapeutic intervention for inflammatory. © 2017 Bentham Science Publishers.-
dc.languageeng-
dc.publisherBentham Science Publishers Ltd. The Journal's web site is located at http://www.bentham.org/cpd/index.htm-
dc.relation.ispartofCurrent Pharmaceutical Design-
dc.subjectBone loss-
dc.subjectIL-17-
dc.subjectIL-17 receptor-
dc.subjectOsteoclastogensis-
dc.subjectOsteoclasts-
dc.titlePivotal roles of Interleukin-17 as the Epicenter of Bone Loss Diseases-
dc.typeArticle-
dc.identifier.emailZhang, C: zhangcf@hku.hk-
dc.identifier.emailYang, Y: yangyanq@hku.hk-
dc.identifier.authorityZhang, C=rp01408-
dc.identifier.authorityYang, Y=rp00045-
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.2174/1381612823666170519120040-
dc.identifier.scopuseid_2-s2.0-85038004408-
dc.identifier.hkuros279299-
dc.identifier.volume23-
dc.identifier.issue41-
dc.identifier.spage6302-
dc.identifier.epage6309-
dc.identifier.isiWOS:000425351700010-
dc.publisher.placeNetherlands-
dc.identifier.issnl1381-6128-

Export via OAI-PMH Interface in XML Formats

OR

Export to Other Non-XML Formats